EC-3, an inhibitor of α4β1 and α4β7 integrins

• US 6,818,617 B1
• Filed: 02/07/2000
• Issued: 11/16/2004
• Est. Priority Date: 08/15/1997
• Status: Expired due to Fees

• Current Assignee: Temple University of The Commonwealth System of Higher Education
• Original Assignee: Temple University of The Commonwealth System of Higher Education
• Inventors: Niewiarowski, Stefan, Marcinkiewicz, Cezary
• Primary Examiner(s): Wax, Robert A.
• Application Number:
  US09/485,323
• Time in Patent Office: 1,744 Days
• Field of Search: 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/18, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329, 530/330, 530/331, 530/344, 530/412, 530/415, 530/856, 424/183.1, 424/173.1, 424/184.1, 435/7.1, 435/7.8
• US Class Current: 514/9.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/46 from vertebrates
• CPC Class Codes: C07K 14/745 Blood coagulation or fibrinolysis factors
• CPC Class Codes: Y10S 530/856 Snakes; venom

Abstract

This invention relates to the identification, purification, and characterization of a novel heterodimeric disintegrin, EC-3, from Echis carinatus viper venom. EC-3 inhibits α4 integrins in an RGD-independent manner. The invention further relates to methods of using EC-3, or a biologically active fragment or derivative thereof, to inhibit the interaction between cells expressing α4 integrins and cellular ligands.

Claims

1. A substantially purified EC3 protein isolated from Echis carinatus venom, characterized by:

(a) an apparent molecular mass of about 14,762 Da, as determined by electrospray ionization mass spectrometry;

(b) elution from a C-18 high performance liquid chromatography column at about 40% acetonitrile; and

(c) the ability to inhibit adhesion of Jurkat cells to vascular cell adhesion molecule-1.

8. The substantially purified EC-3 protein of claim 1 comprising two subunits, wherein one subunit comprises the sequence SEQ ID NO:

19 or a fragment characterized by the ability to inhibit adhesion of K562 cells to fibronectin thereof and one subunit comprises the sequence SEQ ID NO;

20 or a fragment characterized by the ability to inhibit adhesion of Jurkat cells to vascular cell adhesion molecule-1 thereof.

15. A composition comprising a pharmaceutically acceptable carrier and the protein or peptide of any of claims 1-12, or a pharmaceutically acceptable salt thereof.

16. A method of inhibiting the binding of an α

4 integrin to VCAM-1 comprising contacting a cell that expresses the α

4 integrin with an effective amount of a protein or peptide according to one of claims 1-12, or a pharmaceutically acceptable salt thereof.

17. The method of claim 16 wherein the integrin is α

4β

1 or α

4β

7.

18. A method of inhibiting the binding of an α

4β

7 integrin to MadCAM-1 comprising contacting a cell that expresses α

4β

7 with an effective amount of a protein or peptide according to one of claims 1-12, or a pharmaceutically acceptable salt thereof.

19. A method of inhibiting the binding of an α

4 integrin to CS-1 comprising contacting a cell that expresses the α

4 integrin with an effective amount of a protein or peptide according to one of claims 1-12, or a pharmaceutically acceptable salt thereof.

20. A method of inhibiting the interaction between cells expressing an α

4 integrin and VCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition according to claim 15.

21. A method of inhibiting the interaction between cells expressing an α

4 integrin and MadCAM-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition according to claim 15.

22. A method of inhibiting the interaction between cells expressing an α

4 integrin and CS-1 in a patient in need of such treatment comprising administration of a therapeutically effective amount of a composition according to claim 15.

2. A substantially purified EC-3A peptide isolated from EC-3 protein which has been reduced and alkylated, characterized by:

(a) a molecular mass of about 8478 Da in its ethylpyridylated form, as determined by electrospray ionization mass spectrometry;

(b) elation from a C-18 high performance liquid chromatography column at about 42% acetonitrile; and

(c) the ability to inhibit adhesion of K562 cells to fibronectin.

4. The substantially purified EC-3A peptide of claim 2 comprising a sequence represented by SEQ ID NO:

19 or a fragment characterized by the ability to inhibit adhesion of K562 cells to fibronectin thereof.

5. The substantially purified EC-3A peptide of claim 2 comprising a sequence represented by SEQ ID NO:

2.

3. A substantially purified EC-3B peptide isolated from EC-3 protein which has been reduced and alkylated with vinylpyridine, characterized by:

(a) a molecular mass of about 7950 Da in its carboxymethylated form, as determined by electrospray ionization mass spectrometry;

(b) elution from a C-18 high performance liquid chromatography column at about 46% acetonitrile; and

(c) the ability to inhibit adhesion of Jurkat cells to vascular cell adhesion molecule-1.

6. The substantially purified EC-3B peptide of claim 3 comprising a sequence represented by SEQ ID NO:

20, or a fragment characterized by the ability to inhibit adhesion of Jurkat cells to vascular cell adhesion molecule-1 thereof.

7. The substantially purified EC-3B peptide of claim 3 comprising a sequence represented by SEQ ID NO:

3.

9. The substantially purified EC-3B peptide of claim 6, wherein the biologically active fragment comprises a peptide represented by an amino acid sequence X-Y-Met-Leu-Asp-Z, where X is H or a blocking group, Y is zero or more amino acids, and Z is OH or zero or more amino acids.

10. The substantially purified EC-3B peptide of claim 9, wherein the biologically active fragment comprises a peptide having from about 3 to about 20 amino acids.

11. The substantially purified EC-3B peptide of claim 9, wherein the biologically active fragment is represented by SEQ ID No:

16.

12. The substantially purified EC-3B peptide of claim 9, wherein the biologically active fragment is represented by SEQ ID No. 14.

13. A substantially purified echistatin polypeptide represented by SEQ ID NO:

9, in which the Arg-Gly-Asp residues at positions 24-26 are replaced by M et-Leu-Asp.

14. A method of isolating a peptide from a venom, wherein the peptide binds to an integrin of interest, comprising:

(a) dissolving venom in a solvent,

(b) centrifuging the dissolved venom to remove high molecular weight proteins,

(c) fractionating the supernatant from step (b),

(d) immobilizing the fractions from step (c) on a solid support,

(e) adding detectably labeled cells that express the integrin of interest to the immobilized fractions,

(f) detecting the number of cells bound to each immobilized fraction, and

(g) isolating peptide from those fractions which showed enhanced cell binding in step(f).

23. A substantially purified EC-3A peptide characterized by:

(a) a sequence having greater than 90% sequence identity with SEQ ID NO;

2; and

(b) the ability to inhibit adhesion of K562 cells to fibronectin.

24. A substantially purified EC-3B peptide characterized by:

(a) a sequence having greater than 90% sequence identity with SEQ ID NO;

3; and

(b) the ability to inhibit adhesion of Jurkat cells to VCAM-1.